[Current position of beta-adrenergic blockers in the management of arterial hypertension].

Abstract

Discussed is the actual controversy concerning the role of P-adrenergic blocking agents in the treatment of arterial hypertension. The author argues that these drugs are not suitable for elderly hypertensive patients, particularly in primary stroke prevention. The diabetogenic and atherogenic potential of these agents is marginal, and there are no marked differences between the available P blockers (atenolol has possibly some slight disadvantages). However, for the time being these drugs remain in the first line antihypertensive armamentarium for the younger hypertensive patients; for compelling indications or intolerance of other antihypertensives should be prescribed to any patient, as Croatian Society of Hypertension concluded in 1999.

• Authors: Zvonko Rumboldt
• Journal: Lijecnicki vjesnik (Lijec Vjesn) 2007 Jun-Jul Vol. 129 Issue 6-7 Pg. 237-40 ISSN: 0024-3477 [Print] Croatia
• Vernacular Title: Mjesto betaadrenergickih blokatora u suvremenom lijecenju arterijske hipertenzije.
• PMID: 18018716 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Adrenergic beta-Antagonists

Topics

• Adrenergic beta-Antagonists (therapeutic use)
• Humans
• Hypertension (drug therapy)